abstract |
The present invention relates to a pharmaceutical combination for the treatment of manic manifestations associated with schizophrenia and bipolar disorder, comprising a compound active at the microamine-related receptor 1 (TAAR1 agonist) and an antipsychotic drug. It has been surprisingly found that the combination can reduce the metabolic side effects seen with antipsychotic drugs alone. |